Ibrutinib, alone or with rituximab, outperforms bendamustine and rituximab in older patients with previously untreated chronic lymphocytic leukaemia (CLL), according to findings presented at ASH 2018. In study released at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, and published concurrently in the New England Journal of Medicine, 547 patients from ...
“Ibrutinib is the efficacy standard”: targeted therapy pips chemo in CLL
By Mardi Chapman
5 Dec 2018